Apremilast,an oral phosphodiesterase 4 inhibitor,improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized,controlled trials |
| |
| Authors: | D. Thaçi A. Kimball P. Foley Y. Poulin E. Levi R. Chen S.R. Feldman |
| |
| Affiliation: | 1. Comprehensive Center for Inflammation Medicine, University Hospital Schleswig‐Holstein, Lübeck, Germany;2. Harvard Medical School, Boston, MA, USA;3. Skin & Cancer Foundation Inc., St. Vincent's Hospital, The University of Melbourne, Melbourne, Vic., Australia;4. Centre de Recherche Dermatologique du Québec métropolitain, Québec, QC, Canada;5. Celgene Corporation, Summit, NJ, USA;6. Wake Forest University School of Medicine, Winston‐Salem, NC, USA |
| |
| Abstract: | |
| |
| Keywords: | |
|
|
